ATE237697T1 - Verfahren zur vorhersage der effektivität der behandlung von tumoren durch in-vitro bestimmung der überlebens- und vermehrungsfähigkeit - Google Patents

Verfahren zur vorhersage der effektivität der behandlung von tumoren durch in-vitro bestimmung der überlebens- und vermehrungsfähigkeit

Info

Publication number
ATE237697T1
ATE237697T1 AT94922483T AT94922483T ATE237697T1 AT E237697 T1 ATE237697 T1 AT E237697T1 AT 94922483 T AT94922483 T AT 94922483T AT 94922483 T AT94922483 T AT 94922483T AT E237697 T1 ATE237697 T1 AT E237697T1
Authority
AT
Austria
Prior art keywords
effectiveness
vitro
tumors
reproduce
predicting
Prior art date
Application number
AT94922483T
Other languages
English (en)
Inventor
Kenneth M Connors
Anna Monosov
Original Assignee
Anticancer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anticancer Inc filed Critical Anticancer Inc
Application granted granted Critical
Publication of ATE237697T1 publication Critical patent/ATE237697T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT94922483T 1993-06-29 1994-06-29 Verfahren zur vorhersage der effektivität der behandlung von tumoren durch in-vitro bestimmung der überlebens- und vermehrungsfähigkeit ATE237697T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8440293A 1993-06-29 1993-06-29
PCT/US1994/007476 WO1995001455A1 (en) 1993-06-29 1994-06-29 NATIVE-STATE METHOD AND SYSTEM FOR DETERMINING VIABILITY AND PROLIFERATIVE CAPACITY OF TISSUES $i(IN VITRO)

Publications (1)

Publication Number Publication Date
ATE237697T1 true ATE237697T1 (de) 2003-05-15

Family

ID=22184744

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94922483T ATE237697T1 (de) 1993-06-29 1994-06-29 Verfahren zur vorhersage der effektivität der behandlung von tumoren durch in-vitro bestimmung der überlebens- und vermehrungsfähigkeit

Country Status (5)

Country Link
EP (1) EP0714448B1 (de)
AT (1) ATE237697T1 (de)
AU (1) AU7357894A (de)
DE (1) DE69432517T2 (de)
WO (1) WO1995001455A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE429514T1 (de) 2002-11-12 2009-05-15 Anticancer Inc Erstellung von expressionsprofilen auf der grundlage von histokulturen
EP4271995A4 (de) * 2020-12-31 2024-11-20 Elephas Biosciences Corporation Ex-vivo-systeme und verfahren zur bestimmung der wirkung eines arzneimittels oder eines anderen mittels auf ein gewebe

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990011371A1 (en) * 1989-03-20 1990-10-04 Anticancer Inc. NATIVE-STATE METHOD AND SYSTEM FOR DETERMINING VIABILITY AND PROLIFERATIVE CAPACITY OF TISSUES $i(IN VITRO)

Also Published As

Publication number Publication date
WO1995001455A1 (en) 1995-01-12
DE69432517D1 (de) 2003-05-22
EP0714448A1 (de) 1996-06-05
AU7357894A (en) 1995-01-24
EP0714448B1 (de) 2003-04-16
DE69432517T2 (de) 2003-12-24
EP0714448A4 (de) 1998-05-20

Similar Documents

Publication Publication Date Title
DE69635671D1 (de) Verwendung von roxithromycin zur herstellung eines medikaments zur verbesserung der biologischen und antiviralen aktivität von protease-inhibitoren
DE69828408D1 (de) Naphthyridinone zur hemmung der durch protein-tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
TR199802385T2 (xx) TNF inhibit�rleri ve FDE-IV inhibit�rleri olarak kinolin karboksamidler.
BR9408025A (pt) Compostos de peptidila e seu uso terapêutico como inibidores de metaloproteinases
DE60032795D1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
DE60036025D1 (de) Verfahren zur behandlung von hautkrebs mittels zusammensetzungen, die einen endothelinrezeptor-b-hemmer enthalten
ES2133807T3 (es) Compuestos de peptidilo y su uso terapeutico como inhibidores de metaloproteasas.
DE3880118D1 (de) Verwendung eines mittels in form von mikrokapseln zur schabenbekaempfung.
WO1993021942A3 (en) Use of mmp inhibitors
DE69826695D1 (de) Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
ATE79720T1 (de) Verfahren zur konservierung von transplantierbaren, in vitro kultivierten epithelgeweben.
BR9610480A (pt) Inibição do fator alfa de necrose tumoral
DE69535264D1 (de) Verfahren zur behandlung von diabetes mittels kgf
DE69715000D1 (de) Verabreichung von gm-csf zur behandlung der gehirntumoren und verhütung deren wiederauftretens
ATE428928T1 (de) Verfahren zur einführung von heterologischen zellen in fische
ATA903489A (de) Protoporphyrinogeninhibitoren und deren verwendung in zusammensetzungen zur erkennung und behandlung von tumoren
ATE382061T1 (de) Mittel zur induktion von apoptosis und zur therapieanwendung
HU9301677D0 (en) Polypeptide-type compounds of medical effect
ATE371031T1 (de) Herpes-simplex virus, das das gen von interleukin-12 exprimiert, und dessen verwendung zur behandlung von krebs
ATE275968T1 (de) Mitteln zur behandlung von auto-immun krankheiten
DE69725882D1 (de) Adenovirus e4 proteine für induktion von zelltod
IT1203494B (it) Metodo per determinare la concentrazione di microbi mediante distribuzione su piastra e piatti impiegati in esso
ES473474A1 (es) Procedimiento para descubrir sustancias cancerigenas y subs-tancias anticancerosas
ATE237697T1 (de) Verfahren zur vorhersage der effektivität der behandlung von tumoren durch in-vitro bestimmung der überlebens- und vermehrungsfähigkeit

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties